Back to mobile site

More on NRGX

- Summary
- Chart
- Profile
- Historical

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

NRGX Cash Flow Statement

Click line-items for a historical chart and %
Net loss -5.03M
Depreciation 22K
Amortization 62K
Gain on redemption of investment 0
Stock options granted for services 0
Impairment of intangible assets 0
Amortization of deferred financing cost and discount on notes payable 1.62M
Amortization of non-employee share-based compensation 158K
Share-based employee compensation expense 371K
Non-cash interest expense 0
Change in estimated fair value of derivative financial instruments - warrants -2.67M
(Increase) decrease in prepaid expenses and other current assets -75K
Increase (decrease) in accounts payable and accrued expenses 1.07M
Net cash used in operating activities -4.47M
Security deposits paid 0
Purchases of equipment 0
Additions to intangible assets -134K
Proceeds from redemption of investment 0
Purchases of marketable securities 0
Proceeds from maturities of marketable securities 0
Net cash used in investing activities -134K
Proceeds from note payable 0
Borrowings from related party 0
Cash acquired in Merger 0
Merger-related costs 0
Payments of capital lease obligations 0
Proceeds from exercise of stock options 0
Proceeds from issuance of common stock and warrants 0
Proceeds from issuance of preferred stock 0
Net cash provided by financing activities 0
Net (decrease) increase in cash and cash equivalents -4.6M
Cash and cash equivalents, beginning of period 8.06M
Cash and cash equivalents, end of period 3.45M
Dividends on Series C Preferred Stock paid in preferred shares 0
Accrued dividends on Preferred Stock 1.67M
Accretion of fair value of beneficial conversion on preferred stock 0
Accretion of contingent beneficial conversion related on Series C Preferred Stock 0
Induced conversion of preferred stock in connection with issuance of Series D Preferred Stock 0
Issuance of Common Stock to pay debt 0
Reverse acquisition - net liabilities assumed, excluding cash 0
Mandatory redeemable convertible preferred stock converted to Common Stock 0
Common Stock issued to acquire intangible assets 0
Stock options granted for services 0
Deferred research and development cost resulting from Medtronic Stock Purchase 0
Acquisition of equipment through capital leases 0

Entities mentioned with NRGX

View All Entities